about
Proteomic and Metabolomic Analyses Reveal Contrasting Anti-Inflammatory Effects of an Extract of Mucor Racemosus Secondary Metabolites Compared to DexamethasoneStriking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocyclesDicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.DNA or protein? Capillary zone electrophoresis-mass spectrometry rapidly elucidates metallodrug binding selectivity.Heteropentanuclear Oxalato-Bridged nd-4f (n=4, 5) Metal Complexes with NO Ligand: Synthesis, Crystal Structures, Aqueous Stability and Antiproliferative ActivityHalf-sandwich ruthenium(II) biotin conjugates as biological vectors to cancer cells.Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity.Combined Proteome and Eicosanoid Profiling Approach for Revealing Implications of Human Fibroblasts in Chronic Inflammation.Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent.Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity.Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established.Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes.Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging.From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action.An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action.The metalation of hen egg white lysozyme impacts protein stability as shown by ion mobility mass spectrometry, differential scanning calorimetry, and X-ray crystallography.Selective targeting of PARP-1 zinc finger recognition domains with Au(iii) organometallics.Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS.Aquaporins in cancer development: opportunities for bioinorganic chemistry to contribute novel chemical probes and therapeutic agents.Efficiently Detecting Metallodrug-Protein Adducts: Ion Trap versus Time-of-Flight Mass AnalyzersSerum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MSDual Triggering of DNA Binding and Fluorescence via Photoactivation of a Dinuclear Ruthenium(II) Arene ComplexFragmentation methods on the balance: unambiguous top–down mass spectrometric characterization of oxaliplatin–ubiquitin binding sitesNovel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agentsBiomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteinsCapillary zone electrophoresis and capillary zone electrophoresis–electrospray ionization mass spectrometry studies on the behavior of anticancer cis- and trans-[dihalidobis(2-propanone oxime)platinum(II)] complexes in aqueous solutionsPyrone derivatives and metals: From natural products to metal-based drugsNew Variations on the Theme of Gold(III) C∧N∧N Cyclometalated Complexes as Anticancer Agents: Synthesis and Biological CharacterizationAm(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug developmentPost-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissueTime-dependent shotgun proteomics revealed distinct effects of an organoruthenium prodrug and its activation product on colon carcinoma cells
P50
Q28550466-AE3D9B19-000A-4E12-B63C-AFF8F5DAD40EQ30623124-6CE8EE73-F1B4-434E-9F28-C47FFE05E27EQ37148450-53A0B7ED-17F2-4791-B5A2-32AC2201B091Q38105454-E9C5DE04-811B-415A-9E8E-011745AF3E6EQ38287682-AA95304A-5197-44CB-99DE-DB00F59787ADQ38287806-53A1AF78-F5D9-420B-9B60-2D0307169BFDQ38844730-B1D744D2-0EA6-4F56-A2F7-5E15112D4CB3Q38910350-CE06C470-5CF2-43FD-A8E8-E20E1A1B034CQ38939454-B5BAA41A-F135-48F6-B7B4-394B871AB87CQ38957088-51270874-6E80-441B-8646-E32E7122499DQ38990666-81AC31CD-FBC2-40F3-8B45-3384C710419FQ39022215-7B345AB8-0267-4291-84EF-D55BE44C7F64Q39029609-8F1C78C3-2C52-46B4-A1A8-5648388824B0Q39069440-DFD829A3-E0DA-44C5-93E7-B52029F270A6Q39136834-1A22E1DC-4280-4941-8557-75EE8D76B12BQ39146826-39E301C6-9AE6-4C80-A633-E8FDA3F136E6Q39179140-DF4D5FFB-8950-4477-B4CE-F8C12117F71CQ39399932-E8A475A6-8401-444B-AF09-20C105646C18Q39613628-96FFA0B5-27EC-4FE0-9FA3-7A7B021CBAB1Q39668334-5DC56CC6-4523-40D4-ADD5-817A49C968E5Q47196925-1A8CD551-7D55-4800-BBBD-294084404A91Q48088409-828757EE-F3E0-4FBD-A7BD-70A793B8E4F1Q49687144-5E617257-6A6B-4643-9A2D-59EE8504869FQ50015296-BFB0C50D-5731-4923-8BE5-417E70B6C8DDQ51080178-F14C7EF9-A181-44F8-A84D-7EBB2B2516D1Q52401743-A18F095C-34B6-49C0-A2B7-79A168E0F575Q52669693-2E7FF8F7-9250-4518-A086-8791D3E1F639Q53819589-D1ED5625-642A-41BF-AD2E-18DB23896367Q57693530-38600E71-8ECB-496F-B076-DD15F89D5BD6Q58702760-B35C13B8-E33E-4F7A-9134-6EB374908475Q59986430-E076F906-10A4-4845-A41F-6A01D954274CQ60212497-865A4997-9F6F-455B-8B1F-D4AD0B05DE78Q60240420-C22E1E68-4810-4327-8584-918C6EDE7E28Q60240425-715837DA-C682-4DC2-8FEF-5EAD41C5FF18Q60240428-165FBC60-603C-46D1-A01F-A235A777C4B7Q60240447-3B3C04D7-2B57-4192-81D1-6A3B5864F3C8Q63927816-836F3076-A413-4C3A-8D84-C7E75B5DE0ECQ85937659-85032A19-0074-44EB-B029-FA503BB40F18Q88246342-BA5CF154-4D0D-4303-9EE6-8670D471CA7FQ90936183-F3ACA73A-DACB-4321-9349-41DE01EAD1F5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Samuel M Meier
@nl
Samuel M Meier
@sl
Samuel M. Meier
@en
Samuel M. Meier
@es
type
label
Samuel M Meier
@nl
Samuel M Meier
@sl
Samuel M. Meier
@en
Samuel M. Meier
@es
altLabel
Samuel M. Meier
@en
Samuel M. Meier-Menches
@en
Samuel Meier
@en
prefLabel
Samuel M Meier
@nl
Samuel M Meier
@sl
Samuel M. Meier
@en
Samuel M. Meier
@es
P106
P1153
16679787700
57194713978
P21
P31
P496
0000-0002-8930-4574